Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2013

View Archived Issues

Researchers identify a novel variant in TREM2 associated with the late-onset form of AD

Approvals and regulatory submissions mark Johnson & Johnson's fourth quarter 2012

SHP-2 as a novel prognostic marker and therapeutic target in gastric cancer

Onyx Pharmaceuticals achieves development goals

Infinity Pharmaceuticals details plans for 2013

Sanofi patents new lysophospholipid receptor agonists

Biscayne Pharmaceuticals to advance GHRH drug research

FDA accepts Ampio Pharmaceuticals' IND for Optina

VistaGen Therapeutics completes final phase I safety study of AV-101

Takeda presents new D-amino acid oxidase inhibitors

Amorfix Life Sciences developing blood test for ALS

New alpha7 nAChR modulators disclosed by Lupin

Increased glucose tolerance and insulin sensitivity seen in Socs3 knockout mouse model

BioInvent reports first results from phase I human antibody candidate study in multiple myeloma

EntreMed begins phase II study of ENMD-2076

Teva Pharmaceutical reports topline results from second phase III study of Nuvigil

New metalloenzyme inhibitors patented by Viamet Pharmaceuticals

New MAbs targeting AXL presented by French scientists

Imaxio acquires orphan drug indicated for a congenital metabolic disease

FDA extends approval of Novartis' Exjade along with companion diagnostic

Cellmid anti-midkine antibodies show promising results in mouse model of diabetic nephropathy

FDA approves use of Avastin as part of second-line therapy for metastatic colorectal cancer

New antitumor agents disclosed at Novartis

New PDE10A inhibitors disclosed by Bristol-Myers Squibb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...